Skip to main content
MCK logo

McKesson Corporation (MCK) Stock: Price, Forecast & Analyst Target

McKesson Corporation (MCK) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $1062.16 (-2.05%), as of the Nov 19, 2026 trading session; market cap $123B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$1062.16 −$22.27 (-2.05%) Market Cap $123B

McKesson Corporation · MCK · NYSE · Healthcare · Medical - Distribution

Research dated 2026-09-12: McKesson moves medicines and medical supplies through healthcare channels while also selling technology, access support and operating services to pharmacies, specialty practices and life-sciences companies. The case depends on whether rising distribution volume keeps producing more gross profit and cash despite the narrow economics of pharmaceutical wholesaling.

Price as of Nov 19, 2026

Key Statistics

92 of 100

MoonshotScore v2 · McKesson (MCK)

Exceptional
Business Quality Solid (60)
Financial Safety Fortress (93)
Valuation Cheap (84)
Growth Durability Compounding (92)
Momentum Surging (92)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet and elite growth, at a cheap price, though quality is only decent; the market is already moving on it. Business Quality: Solid; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 3, 2027
  • Altman Z 5.84 · Piotroski F 7

Helping: balance-sheet strength, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MCK (57 recorded, newest six shown)
RecordedScoreBand
92Exceptional
85Exceptional
92Exceptional
92Exceptional
92Exceptional
92Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1062.16
Change on the day-2.05%
52-week range$723.68–$1121.50
Market capitalisation$123B—
Price / earnings (trailing)27.96
Shares traded on the day611.6K
Beta (volatility vs the S&P 500)0.28

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $736, high $1,103, latest $1,062. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $1,103 $736 high $1,103 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $9491May 7, 2026 · Earnings results · reported above the recorded estimate · close $7362Aug 5, 2026 · Earnings results · reported above the recorded estimate · close $8703Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $1,0614 Oct 17, 2025 Nov 19, 2026 · $1,062 $786Oct 17, 2025$811Oct 31, 2025$842Nov 14, 2025$881Nov 28, 2025$814Dec 12, 2025$828Dec 26, 2025$816Jan 9, 2026$820Jan 23, 2026$949Feb 6, 2026$947Feb 20, 2026$919Mar 6, 2026$886Mar 20, 2026$884Apr 2, 2026$866Apr 17, 2026$814May 1, 2026$761May 15, 2026$742May 29, 2026$784Jun 12, 2026$764Jun 26, 2026$806Jul 10, 2026$841Jul 24, 2026$870Aug 7, 2026$859Aug 21, 2026$908Sep 4, 2026$875Sep 18, 2026$902Oct 2, 2026$1,005Oct 16, 2026$995Oct 30, 2026$1,103Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for McKesson (MCK): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Strong
Valuation Strong
Growth Durability Strong
Momentum Strong

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is McKesson (MCK), and what does it report?

Short answer · as of

Most of McKesson’s revenue comes from distributing branded, generic, specialty, biosimilar and nonprescription medicines in North America.

That makes reported sales largely a measure of product value moving through its network, while gross profit and operating profit better reveal the economic value retained by McKesson.

This is not merely a warehouse-and-delivery business. Oncology and multispecialty services, prescription access technology, pharmacy software and consulting, and medical-surgical logistics add service and technology economics around the distribution network, although pharmaceutical distribution remains dominant by revenue.

2 · Latest results

What do the latest results show for McKesson (MCK)?

Revenue rebounded in the most recent reported period and exceeded the market estimate, while the reported earnings figure also cleared expectations. Gross profit did not share that sequential rebound, and operating profit, net income and statement earnings per share fell sharply from the preceding period.

The longer series is stronger than that snapshot: annual revenue and net income advanced, and recent reported earnings have generally exceeded estimates even when revenue did not. The mechanism to watch is the conversion of medicine volume into retained gross profit, because immense product throughput produces only a slim net margin.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$110.96B Nov 4, 2026
Latest report · revenue estimate
$109.90B Nov 4, 2026
Latest report · revenue vs estimate
Above estimate Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026$110.96B$109.90B$11.6800$10.7200
Aug 5, 2026$105.38B$103.88B$9.9300$9.5600
May 7, 2026$96.30B$101.35B$11.6900$11.5600
Feb 4, 2026$106.16B$105.80B$9.3400$9.1700
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$103.15B$1.11B$8.92 (diluted)
Q3 FY2026$106.16B$1.19B$9.59 (diluted)
Q4 FY2026$96.30B$1.68B$13.71 (diluted)
Q1 FY2027$105.38B$614M$5.15 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for McKesson (MCK)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

McKesson remains profitable, its cash balance has risen across recent reporting periods, and the quality and distress screens are supportive. Cash nevertheless remains below total debt, current assets do not fully cover current liabilities under the reported ratio, and total liabilities are substantial.

Cash generation is lumpy rather than smoothly tracking earnings: operating cash flow turned negative in the latest period after a large positive result previously. With narrow gross, operating and net margins, weaker retained economics on pharmaceutical volume or higher operating costs can affect profit far more severely than the revenue line suggests.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 27.96 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at McKesson (MCK)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

Watch whether revenue growth again brings higher gross profit and whether operating profit recovers from its latest decline. Segment results should also reveal whether oncology and multispecialty services or prescription technology are becoming more meaningful beside the much larger pharmaceutical operation.

Cash conversion deserves equal attention. A return to positive operating cash flow, continued cash accumulation and restraint in debt would strengthen the financial picture; another disconnect between accounting profit and cash flow would make the recent volatility harder to dismiss. The scheduled earnings release provides the next checkpoint, while longer-range consensus assumes continued expansion in revenue and earnings.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does McKesson compare with its peers?

Short answer

McKesson's score ranks 2nd of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

McKesson’s defining feature is the combination of vast pharmaceutical throughput with services embedded deeper in medication delivery. Community oncology support, pharmacy technology, patient access and adherence tools, and medical-surgical logistics give it ways to earn around the medicine transaction that a plain wholesale description leaves out.

That mix does not change the financial signature of a distributor: revenue is enormous relative to the profit retained, and North American pharmaceutical distribution dominates segment sales. Comparison with similar businesses therefore belongs at the gross-profit, operating-profit and cash-conversion level, not on revenue scale alone.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Guardian Pharmacy Services, Inc. (GRDN) Same industry, near in market value$46.66 Nov 19, 2026$2.96B96 5-pillar Nov 18, 2026
McKesson (MCK) — this page$1062.16$123B92
Vertex Pharmaceuticals Incorporated (VRTX) Named competitor$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Same industry, near in market value$272.37 Nov 19, 2026$63.0B88 5-pillar Nov 18, 2026
Sanofi (SNY) Named competitor$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
Cencora, Inc. (COR) Same industry, near in market value$341.25 Nov 19, 2026$65.1B86 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Named competitor$80.06 Nov 19, 2026$102B81 5-pillar Nov 18, 2026
GSK plc (GSK) Named competitor$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Same industry, near in market value$84.80 Nov 19, 2026$9.37B73 5-pillar Nov 18, 2026
Prestige Consumer Healthcare Inc. (PBH) Same industry, near in market value$49.60 Nov 19, 2026$2.35B63 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$845.00 – $1200.00
Consensus target
$998.57
Median target
$1000.00

Consensus record · Captured .

Measured against a quoted price of $1062.16 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026

Transactions
30
Identified insiders
18
Purchases
0
Sales
14
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MCK in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.27%$62.08MAdded +3.3% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about McKesson (MCK)?

Read these with our analysis →

What Investors Ask About McKesson (MCK) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Why does McKesson report enormous revenue but a thin net margin?

Most sales reflect medicines passing through McKesson’s distribution network. The company retains only a narrow portion as gross and operating profit, so revenue scale alone overstates the economics captured by shareholders.

How important is North American Pharmaceutical to McKesson?

North American Pharmaceutical dominates reported segment revenue and supplies branded, generic, specialty, biosimilar and nonprescription medicines. Its scale makes pharmaceutical volume and retained gross profit central to McKesson’s consolidated performance.

What does McKesson’s Prescription Technology Solutions business do?

Prescription Technology Solutions connects pharmacies, providers, payers and biopharmaceutical companies to support medication access and adherence. It also provides logistics and wholesale support, extending McKesson’s role beyond physical distribution.

Why should McKesson investors watch oncology and multispecialty services?

The business supports community specialty practices with technology, clinical guidance, practice tools and broader operating services. It is meaningful within the segment mix and offers service exposure alongside the much larger pharmaceutical distribution operation.

What is the MCK stock price today?

The last price recorded for McKesson Corporation (MCK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MCK price target?

The analyst consensus price target for McKesson Corporation (MCK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 34 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions)
  • 1. What is McKesson (MCK), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • 2. What do the latest results show for McKesson (MCK)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for McKesson (MCK)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Quarterly income statement (USD thousands)
  • 4. What should you watch next at McKesson (MCK)?: Quarterly income statement (USD thousands); Revenue by segment; Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Next earnings report; Analyst revenue and earnings estimates (average)
  • 5. How does McKesson compare with its peers?: Business description; Revenue by segment; Trailing twelve-month ratio set; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: Why does McKesson report enormous revenue but a thin net margin?: Business description; Revenue by segment; Trailing twelve-month ratio set
  • FAQ: How important is North American Pharmaceutical to McKesson?: Revenue by segment; Business description; Quarterly income statement (USD thousands)
  • FAQ: What does McKesson’s Prescription Technology Solutions business do?: Business description; Revenue by segment
  • FAQ: Why should McKesson investors watch oncology and multispecialty services?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold MCK

Funds in our ETF coverage that list MCK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Scharf ETF (KAT)6.13%
SMI 3Fourteen Full-Cycle Trend ETF (FCTE)5.90%
Texas Capital Texas Equity Index ETF (TXS)5.87%
Amplify COWS Covered Call ETF (HCOW)3.10%
Burney U.S. Equity Select ETF (BRES)2.51%
SPCT ETF2.49%
XHS ETF2.40%
JPMorgan U.S. Minimum Volatility ETF (JMIN)0.70%
T. Rowe Price Hedged Equity ETF (THEQ)0.40%